Jun 07, 2017 11:45 am UTC| Business
SOUTH SAN FRANCISCO, Calif., June 07, 2017 -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today...
Jun 07, 2017 11:30 am UTC| Business
New clinical data reported on ppFEV1 measurement taken after washout of alidornase alfa demonstrates meaningful decrease in efficacy parameters once treatment with alidornase alfa stopped further supporting alidornase alfa...
Jun 07, 2017 11:30 am UTC| Business
LA JOLLA, Calif., June 07, 2017 -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that preliminary data from...
Jun 07, 2017 11:30 am UTC| Business
VANCOUVER, British Columbia, June 07, 2017 -- Balmoral Resources Ltd. (“Balmoral” or the “Company”) (TSX:BAR) (OTCQX:BALMF) today announced additional near-surface, high-grade gold results from its Detour Gold Trend...
Amicus Therapeutics to Present at Goldman Sachs 38th Annual Global Healthcare Conference
Jun 07, 2017 11:30 am UTC| Business
CRANBURY, N.J., June 07, 2017 -- Amicus Therapeutics, Inc. (Nasdaq:FOLD) announced today that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the...
Jun 07, 2017 11:07 am UTC| Business
Dublin, June 07, 2017 -- Research and Markets has announced the addition of the "U.S. Pet Market Outlook, 2017-2018" report to their offering. Pet Market Outlook, Packaged Facts...
Jun 07, 2017 11:01 am UTC| Business
- OBE2109 is a GnRH receptor antagonist currently in development as both a stand-alone treatment and with add-back therapy designed to address the needs of endometriosis and uterine fibroid patients - Geneva,...